uric acid has been researched along with febuxostat in 322 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.24) | 18.2507 |
| 2000's | 27 (8.39) | 29.6817 |
| 2010's | 185 (57.45) | 24.3611 |
| 2020's | 106 (32.92) | 2.80 |
| Authors | Studies |
|---|---|
| Higashino, K; Hiroishi, K; Moriwaki, Y; Nasako, Y; Takahashi, S; Yamakita, J; Yamamoto, T | 1 |
| Couch, RC; Griffin, TB; Hasegawa, M; Horiuchi, H; Komoriya, K; Kondo, S; Osada, Y | 1 |
| Fukushima, H; Hasegawa, M; Komoriya, K; Kondo, S; Osada, Y; Takahashi, K; Tsuchimoto, M | 1 |
| Horiuchi, H; Kaneko, H; Kasahara, Y; Kobayashi, M; Komoriya, K; Kondo, S; Nishimura, S; Ota, M | 1 |
| Bomalaski, JS; Clark, MA | 1 |
| Becker, MA; Hunt, B; Joseph-Ridge, N; Khosravan, R; Kisicki, J; MacDonald, P; Mulford, D; Wu, J | 1 |
| Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL | 1 |
| Choy, G | 1 |
| Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Streit, J; Wortmann, RL | 1 |
| Moreland, LW | 1 |
| Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT | 1 |
| Lee, SJ; Terkeltaub, RA | 1 |
| Finley, JM | 1 |
| Hershfield, MS; Sundy, JS | 1 |
| Abeles, AM; Pillinger, MH; Rosenthal, P | 1 |
| Avila-Casado, C; Franco, M; Johnson, RJ; Sánchez-Lozada, LG; Soto, V; Tapia, E; Zhao, L | 1 |
| Joseph-Ridge, N; Khosravan, R; Kukulka, MJ; Vernillet, L; Wu, JT | 1 |
| Hair, PI; Keating, GM; McCormack, PL | 1 |
| Chen, LX; Schumacher, HR | 1 |
| Schlesinger, N | 1 |
| Edwards, NL | 1 |
| Sundy, JS | 1 |
| Becker, MA; Hunt, B; Joseph-Ridge, N; Lademacher, C; Macdonald, PA; Schumacher, HR; Streit, J; Wortmann, RL | 1 |
| Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR | 2 |
| Traynor, K | 1 |
| Becker, MA; Chohan, S | 1 |
| Lioté, F; Perez-Ruiz, F; Scavulli, J; Terkeltaub, R; Zelman, D | 1 |
| Hall, HA; Poon, SH; Zimmermann, B | 1 |
| Ernst, ME; Fravel, MA | 1 |
| Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF | 1 |
| Grabowski, B; Khosravan, R; Lademacher, C; Vernillet, L; Wu, JT | 1 |
| Burns, CM; Wortmann, RL | 1 |
| Quillen, DM | 1 |
| Graser, E; Pope, RS; Zychowicz, ME | 1 |
| Cohen, MG | 1 |
| Hunt, B; Jackson, RL; Macdonald, PA; Wortmann, RL | 1 |
| Dubost, JJ; Mathieu, S; Soubrier, M | 1 |
| Goldfarb, DS; Gunawardhana, L; Hunt, B; MacDonald, PA | 1 |
| El-Armouche, A; Emons, J; Wittköpper, K | 1 |
| Reid, G; Uh, M | 1 |
| Hosoya, T; Kamatani, N; Naoyuki, K; Tatsuo, H | 1 |
| Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H | 2 |
| Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M | 3 |
| Hosoya, T; Iwao, O; Ohno, I; Tatsuo, H | 1 |
| Chohan, S | 1 |
| Goldfarb, DS | 1 |
| Kriegsmann, J; Lange, U; Müller-Ladner, U; Panzner, I; Tausche, AK | 1 |
| Adenwalla, HN; O'Connor, CR | 1 |
| Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA | 1 |
| Becker, MA; Gunawardhana, L; Hunt, B; MacDonald, PA | 1 |
| Das, P; Suresh, E | 1 |
| Hunt, B; Jackson, RL; MacDonald, PA | 1 |
| Richette, P | 1 |
| Doghramji, PP; Mandell, BF; Pope, RS | 1 |
| Carey, JJ; Conway, R; Coughlan, RJ | 1 |
| Herrero-Beites, AM; Perez-Ruiz, F | 1 |
| Keenan, RT | 1 |
| Akimoto, T; Horikoshi, R; Inoue, M; Kusano, E; Morishita, Y | 1 |
| Chen, S; Cheng, Q; Li, Q; Liu, L; Luo, T; Lv, Q; Mei, M; Yang, S; Ye, P; Zhang, W | 1 |
| Chefo, S; Gunawardhana, L; MacDonald, PA; Whelton, A | 1 |
| Von Zingel, M | 1 |
| Bianchi, G; Borghi, C; Bortoluzzi, A; Cimmino, MA; D'Avola, GM; Desideri, G; Di Giacinto, G; Favero, M; Govoni, M; Grassi, W; Lombardi, A; Manara, M; Marangella, M; Matucci Cerinic, M; Medea, G; Minisola, G; Prevete, I; Punzi, L; Ramonda, R; Scirè, CA; Spadaro, A | 1 |
| Hata, H; Hata, M; Nakata, K; Sezai, A; Shiono, M; Soma, M; Wakui, S; Yoshitake, I | 1 |
| Beard, SM; Nuki, G; Pearson, IV; von Scheele, BG | 1 |
| Roberts, J; Seifried, RM | 1 |
| Chefo, S; Goldfarb, DS; Gunawardhana, L; MacDonald, PA; McLean, L | 1 |
| Aringer, M; Bielitz, C; Christoph, M; Forkmann, M; Kopprasch, S; Richter, U; Tausche, AK; Wunderlich, C | 1 |
| Murasawa, T; Ohno, D; Otsuka, T; Sakai, Y; Sato, N; Tsuruoka, S | 1 |
| Hasegawa, K; Hiramitsu, S; Ishiguro, Y; Ishii, J; Kani, A; Kato, H; Kato, K; Kato, Y; Kimura, H; Matsubara, S; Matsubara, Y; Matsuyama, H; Mori, K; Noba, M; Shino, K; Tokuda, M; Uchiyama, T; Uemura, A; Yamada, K; Yoshida, S | 1 |
| Bakris, GL; Doghramji, PP; Keenan, RT; Silber, SH | 1 |
| Ehteshami-Afshar, A; Faruque, LI; Homik, J; Tjosvold, L; Tonelli, M; Wiebe, N | 1 |
| Hayakawa, H; Hosoya, T; Iimuro, S; Imai, N; Inaba, M; Itoh, S; Kimura, K; Kuwabara, M; Makino, H; Matsuo, S; Ohno, I; Shibagaki, Y; Tomino, Y; Uchida, S; Yamamoto, T | 1 |
| Bao, C; Du, H; Gu, J; Huang, A; Huang, X; Jiang, L; Li, J; Li, X; Li, Z; Liu, Y; Zhang, Y; Zhang, Z; Zhao, D; Zhu, P; Zuo, X | 1 |
| Baumgartner, S; Fleischmann, R; Hingorani, V; Kerr, B; Manhard, K; Miner, JN; Polvent, E; Quart, B; Shen, Z; Suster, M; Yeh, LT | 1 |
| Hara, T; Hayashida, Y; Inui, M; Kakehi, Y; Kohno, M; Moriwaki, K; Nishijima, Y; Nishiyama, A; Sofue, T; Ueda, N | 1 |
| Singh, JA | 1 |
| Akhras, KS; Hatoum, H; Khanna, D; Khanna, P; Lin, SJ; Shiozawa, A | 1 |
| Arowojolu, O; Goldfarb, DS | 1 |
| Bardelli, M; Cantarini, L; Galeazzi, M; Rigante, D; Vitale, A | 1 |
| Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W | 1 |
| Ohya, M; Shigematsu, T | 1 |
| Hosoya, T; Kimura, K; Ohno, I; Shibagaki, Y | 1 |
| Itabashi, M; Mochizuki, T; Moriyama, T; Nitta, K; Takei, T; Tsuchiya, K; Tsuruta, Y | 1 |
| Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R | 1 |
| Bennett, K; McGowan, B; Silke, C; Whelan, B | 1 |
| Kataoka, H; Rock, KL; Yang, K | 1 |
| Iwasaki, H; Kishi, S; Matsuda, Y; Nakamura, T; Ookura, M; Tai, K; Takai, M; Ueda, T; Yamauchi, T; Yoshida, A | 1 |
| Dalbeth, N; Robinson, PC | 1 |
| Bottorff, MB; Gandhi, PK; Gentry, WM; Ma, Q | 1 |
| Hata, H; Ishii, Y; Nakata, K; Osaka, S; Sezai, A; Shiono, M; Soma, M; Yaoita, H | 1 |
| Fujimori, S; Hidaka, Y; Higami, K; Hosoya, T; Inaba, M; Ishimura, E; Kakuda, H; Mineo, I; Moriwaki, Y; Nishikawa, H; Ohtawara, A; Ooyama, H; Taniguchi, A; Ueda, T; Yamamoto, T; Yamanaka, H; Yamauchi, T | 1 |
| Asahi, K; Hayashi, Y; Kanno, M; Kimura, H; Nakayama, M; Tanaka, K; Tani, Y; Terawaki, H; Watanabe, K; Watanabe, T | 1 |
| Flipo, RN; Patrikos, DK; Richette, P | 1 |
| Abe, Y; Fukui, T; Maruyama, M; Yamauchi, K; Yasuda, T; Yoshitaka, S | 1 |
| Li, L; Lu, W; Sun, Y; Zhou, TY | 1 |
| Akhras, KS; Shiozawa, A; Singh, JA | 1 |
| Kim, KA; Park, JY | 1 |
| Akiba, T; Itabashi, M; Kikuchi, K; Moriyama, T; Nitta, K; Sasaki, Y; Takei, T; Tsuchiya, K; Tsuruta, Y; Uchida, K | 1 |
| Asano, T; Fujishiro, M; Fukushima, T; Kamata, H; Kanaoka, R; Katasako, A; Kushiyama, A; Matsunaga, Y; Mori, K; Nakatsu, Y; Sakoda, H; Seno, Y; Yamamotoya, T | 1 |
| Chen, S; Ji, H; Ji, Q; Lin, J; Liu, B; Liu, H; Liu, P; Liu, X; Lu, Y; Ming, J; Peng, Y; Wang, J; Wang, Y; Xu, S; Zhang, Y | 1 |
| Hu, SX; Lei, XM; Shen, GF; Ye, C; Yu, F; Yu, YK; Zhang, ST | 1 |
| Nishizawa, T; Nomura, S; Taniura, T | 1 |
| Aurer, I; Baldini, S; Borsaru, G; Bosi, A; Capriati, A; Federico, M; Glushko, NL; Grosicki, S; Jakucs, J; Jordan, K; Maggi, CA; Mayer, J; Montesinos, P; Nagy, Z; Pristupa, AS; Rego, EM; Ribera, JM; Ristic, D; Scartoni, S; Simonelli, C; Spina, M | 1 |
| Aniel-Quiroga, MA; Atxotegi, J; Chinchilla, SP; Herrero-Beites, AM; Perez-Ruiz, F; Urionagüena, I | 1 |
| Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ | 2 |
| Altan, A; Bancroft, T; Shiozawa, A; Singh, JA | 1 |
| Chen, CJ; Chen, DY; Hsu, PN; Lai, JH; Lin, HY; Yu, KH | 1 |
| Aibibula, Z; Ailixiding, M; Asou, Y; Hara, Y; Iwata, M; Okawa, A; Piao, J | 1 |
| Bäurle, A | 1 |
| Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N | 2 |
| Borghi, C; Perez-Ruiz, F | 1 |
| Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T | 1 |
| Mitri, G; Schulman, KL; Tidwell, BA; Turpin, RS; Wittbrodt, ET | 1 |
| Higa, A; Iseki, K; Ishida, A; Kohagura, K; Nagahama, K; Ohya, Y; Sakima, A; Tana, T; Yamazato, M | 1 |
| Chang, NC; Lee, TM; Lin, SZ | 1 |
| Bakinde, N; Mome, R | 1 |
| Filiopoulos, V; Hadjiyannakos, D; Vlassopoulos, D | 1 |
| Sircar, D | 1 |
| Füeßl, HS | 1 |
| Echizen, H; Hirai, T; Kimura, T | 1 |
| Andrés, M; Gil, S; Pascual, E; Quilis, N; Ranieri, L; Vela, P | 1 |
| Ako, J; Bando, YK; Eguchi, K; Higashi, Y; Inoue, T; Ishizaka, N; Ishizu, T; Kanzaki, Y; Kuroyanagi, T; Maemura, K; Murohara, T; Node, K; Ohishi, M; Oyama, J; Sata, M; Sato, Y; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamada, H | 1 |
| Christensen, HD; Hansen, IM; Morillon, MB; Sheta, HM | 1 |
| Agrawal, A; Saigal, R | 1 |
| Arima, H; Hayashi, S; Ishizuka, A; Iwashima, Y; Kawano, Y; Kishida, M; Nakamura, S; Ohta, Y; Yoshihara, F | 1 |
| Day, RO; Graham, GG; Kamel, B; Kannangara, DR; Williams, KM | 1 |
| Carroll, MB; Shaak, TL; Smith, DM | 1 |
| Li, Y; Lu, Y; Meng, J; Yuan, X | 1 |
| Bryant, CL; Fourakre, TN; Hughes, JC; Salvig, BE; Stone, WJ; Wallace, JL | 1 |
| Stamp, LK | 1 |
| Chen, X; Su, J; Tian, J; Zhou, Q; Zhou, T; Zhu, J | 1 |
| Corbett, EJM; McGill, NW; Pentony, P | 1 |
| Abd El-Raouf, OM; Gad, AM; Khalaf, MM; Khames, A | 1 |
| Advani, A; Cherney, DZI; Fong, D; Har, R; Lai, V; Locke, A; Lytvyn, Y; Perkins, BA | 1 |
| Deeks, ED | 1 |
| Chen, H; Jiang, L; Kong, X; Ma, L; Sun, Y; Zhang, X; Zhang, Z; Zhou, J; Zhou, Y | 1 |
| Neogi, T; Vargas-Santos, AB | 1 |
| Hira, D; Ikeda, Y; Katsube, Y; Koide, H; Minegaki, T; Morita, SY; Nishiguchi, K; Terada, T; Tsujimoto, M; Uzu, T | 1 |
| Fan, CX; Li, L; Liang, YL; Lin, ZM; Liu, XN; Qu, JC; Xu, X; Zhang, RS; Zhao, HY; Zhao, L; Zhu, KS | 1 |
| Alshahawey, M; Elsaid, TW; Sabri, NA; Shahin, SM | 1 |
| Harada, M; Hashimoto, K; Kamijo, Y; Yamada, Y; Yamaguchi, A | 1 |
| Adler, S; Baumgartner, S; Bhakta, N; Dalbeth, N; Fung, M; Jones, G; Khanna, D; Kopicko, J; Perez-Ruiz, F; Storgard, C; Terkeltaub, R | 1 |
| Abe, K; Kanno, S; Obata, K; Sekino, H; Sezai, A | 1 |
| Kim, JW; Kwak, SG; Park, SH | 1 |
| Mitsuboshi, S; Nagai, K; Okajima, H; Yamada, H | 1 |
| Hill-McManus, D; Hughes, D; Lane, S; Marshall, S; Soto, E | 2 |
| Choi, HK; Dalbeth, N; Gunawardhana, L; Hunt, B; MacDonald, PA; Palmer, WE; Saag, KG; Thienel, U | 1 |
| Hori, D; Kishimoto, K; Kobayashi, K; Kobayashi, R; Sano, H; Suzuki, D | 1 |
| Cimmino, MA; Cutolo, M; Perez-Ruiz, F | 1 |
| Fukae, M; Hirakawa, M; Hirota, T; Ieiri, I; Kakara, M; Moriki, K; Muraki, S; Shigematsu, S; Shimada, M; Takane, H; Yamashita, D | 1 |
| Ishii, T; Oyama, K; Taguri, M; Tamura, K | 1 |
| Borghi, C; Bove, M; Cicero, AFG | 1 |
| Fujimori, S; Hidaka, Y; Ide, Y; Inoue, K; Kim, H; Sugimoto, M; Tamaki, S; Taniguchi, A; Yamamoto, T; Yamanaka, H | 1 |
| Feig, DI; Gunawardhana, L; Hunt, B; McLean, L; Palmer, RN; Punzi, HA; Whelton, A | 1 |
| Chiu, HT; Chou, HW; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC | 1 |
| Baek, CH; Han, DJ; Kim, H; Park, SK; Yang, WS | 1 |
| Case, R; Jester, G; Wentworth, B | 1 |
| Treviño-Becerra, A | 1 |
| Chang, WX; Kumagai, T; Shibata, S; Tamura, Y; Uchida, S | 1 |
| Aksenov, S; Eriksson, UG; Peck, CC; Stanski, DR | 1 |
| Kuehn, BM | 1 |
| Lioté, F; Pascart, T | 1 |
| Brittan, K; Brophy, M; Davis-Karim, A; Henrie, AM; Mikuls, TR; Neogi, T; Newcomb, J; O'Dell, JR; Palevsky, PM; Pillinger, MH; Pittman, D; Taylor, TH; Timilsina, S; Wu, H | 1 |
| Maalouf, NM; Marin, M | 1 |
| Gillen, M; Hall, J; Shen, Z; Yang, X | 1 |
| Fujigaki, Y; Goto, D; Kato, A; Ohashi, N; Ohishi, K; Sato, T; Takeda, A; Tsuji, T; Yasuda, H | 1 |
| McHugh, J | 1 |
| Cho, YS; Han, N; Kim, YS; Kwak, CH; Oh, JM; Sohn, M | 1 |
| Bao, H; Cheng, J; Liu, X; Peng, A; Qin, L; Song, Y; Wang, L; Yu, H; Zhou, X | 1 |
| Gillen, M; Hall, J; Ito, Y; Liu, S; Shen, Z; Shiramoto, M; Yamamoto, A; Yan, X | 1 |
| Echizen, H; Hirai, T; Itoh, T; Kimura, T | 1 |
| Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A | 1 |
| Chen, X; Gu, B; Li, C; Qian, K; Ren, Q; Shen, M; Su, D; Wang, X; Xu, W; Yang, L; Yuan, H; Zhang, J | 1 |
| Cheetham, TC; Levy, G; Rashid, N; Shi, JM | 1 |
| Wang, S | 1 |
| Nakano, Y; Otsuka, F | 1 |
| Gunawardhana, L; White, WB | 1 |
| Bhattacharyya, S; Macklin, EA; Schwarzschild, MA | 1 |
| Bartsch, LA; Ortiz, A; Perez-Gomez, MV | 1 |
| Lundberg, JO; Montenegro, MF; Weitzberg, E | 1 |
| Robinson, PC | 1 |
| Fields, TR | 1 |
| Badve, SV; Johnson, DW; Tiku, A | 2 |
| Hao, YJ; Ji, LL; Zhang, ZL | 1 |
| Chen, P; Chen, X; Fu, Q; Gao, X; Li, J; Liu, L; Shen, X; Wang, C | 1 |
| Bardin, T; Richette, P | 1 |
| Lee, JW; Lee, KH | 1 |
| Chen-Xu, M; Choi, HK; Pillinger, MH; Rai, SK; Yokose, C | 1 |
| Gupta, MK; Singh, JA | 1 |
| Borghi, C; Mancia, G; Narkiewicz, K | 1 |
| Chen, JR; Chen, SL; Yang, SW | 1 |
| Masi, S; Pugliese, NR; Taddei, S | 1 |
| Kim, JM; Kim, SH; Lee, SY; Son, CN | 1 |
| Bellos, I; Kontzoglou, K; Pergialiotis, V; Psyrri, A | 1 |
| Hill-McManus, D; Hughes, DA; Marshall, S; Soto, E | 1 |
| Ahn, C; Bae, EH; Choi, HS; Kim, CS; Kim, SW; Kim, YS; Ma, SK; Oh, KH; Oh, TR; Sung, SA | 1 |
| Burnier, M; Messerli, FH | 1 |
| Li, Y; Liu, M; Lu, Y; Meng, J; Zhang, X | 1 |
| Deng, JX; Jie, LG; Qu, Y; Wu, J; Yu, QH; Zhang, YP | 1 |
| Chen, YC; Hung, LY; Lin, CH; Lin, TC; Lo, WC; Tam, KW; Wu, MY | 1 |
| Araujo, E; Baraf, HSB; Bayat, S; Cavallaro, A; Ellmann, H; Kleyer, A; Lell, M; Manger, B; Rech, J; Schenker, H; Schett, G; Simon, D; Tascilar, K | 1 |
| Chang, WC; Chen, TC; Hsu, FS; Hwang, JJ; Lee, CC; Liu, CW; Lo, C; Shau, WY; Wang, ML | 1 |
| Hisatome, I; Kondoh, H; Matsumura, Y; Ohtahara, A; Takeda, T; Teramoto, K | 1 |
| Chuang, HY; Hsu, CN; Huang, SH; Huang, YB; Lee, CT; Peng, YL; Tain, YL; Tsai, CY; Wen, YH | 1 |
| Cheng, X; Cui, L; He, Y; Ji, A; Li, C; Li, H; Liang, N; Ma, L; Sun, M; Sun, R; Sun, W; Wang, C; Wu, X; Xu, T; Xue, X; Yuan, X; Zhang, H | 1 |
| Chen, JS; Chiou, MJ; Chung, TT; Hsieh, AH; Kuo, CF; Lan, WC; Luo, SF; Tseng, WY; Wang, LC; Yu, KH | 1 |
| Asano, T; Fujishiro, M; Inoue, MK; Kikuchi, T; Kushiyama, A; Masaki, T; Matsunaga, Y; Mizuno, Y; Morii, K; Nakatsu, Y; Ono, H; Sakoda, H; Sasaki, K; Takahashi, M; Ueda, K; Yamamotoya, T | 1 |
| Abu-Risha, SE; Amer, MS; El-Mahdy, NA; Saleh, DA | 1 |
| Yang, AY | 1 |
| Osaka, S; Sekino, H; Sezai, A; Tanaka, M; Taoka, M; Unosawa, S | 1 |
| Chaumont, M; Coremans, C; Cullus, P; De Becker, B; Delporte, C; Franck, T; Rousseau, A; Van Antwerpen, P; van de Borne, P; Zouaoui Boudjeltia, K | 1 |
| Kuriyama, S | 1 |
| Cheung, PP; Chua, CKT; Lim, AYN; Santosa, A; Teng, GG | 1 |
| Han, H; Li, X; Tian, J; Yan, Z; Ye, F; Zhang, X | 1 |
| Chen, G; Honda, M; Kaneko, S; Matsui, C; Mizukoshi, E; Nagashimada, M; Nagata, N; Ni, Y; Nishikawa, T; Ota, T; Sakai, Y; Shimakami, T; Shirakura, T; Xu, L; Yamashita, T; Zhuge, F | 1 |
| Furuno, K; Hosoya, T; Kanda, S | 1 |
| Afsar, B; Cherney, D; Covic, A; Dincer, N; Erden, N; Kanbay, M; Kuwabara, M; Ortiz, A; Rossignol, P; Sag, AA; Siriopol, D; Yilmaz, O | 1 |
| Bathini, T; Chang, YT; Cheungpasitporn, W; Chewcharat, A; Crisafio, A; Mao, MA; Thongprayoon, C | 1 |
| Choi, SW; Choi, SY; Lee, S; Lim, DH; Oh, JS; So, MW | 1 |
| Cao, L; Wan, WG; Xue, Y; Yang, X; Zhao, L; Zhao, TY; Zhu, XX; Zou, HJ | 1 |
| Ansari, MT; Chouhan, D; Shankar, V | 1 |
| Eguchi, K; Higashi, Y; Ishibashi, R; Ishizaka, N; Ishizu, T; Kanzaki, Y; Kario, K; Kato, T; Maemura, K; Murohara, T; Node, K; Ohishi, M; Oyama, JI; Sata, M; Sezai, A; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S; Yamada, H; Yokote, K | 1 |
| Gu, SW; Huang, YY; Jiang, ZY; Ye, Z; Zhao, L | 1 |
| Carland, JE; Day, RO; Graham, GG; Kamel, B; Liu, Z; Pile, KD; Stocker, SL; Williams, KM | 1 |
| Lin, CJ; Lin, JY; Shi, Y; Sun, SS; Zhang, DH | 1 |
| Brown, JN; Hu, AM | 1 |
| Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF | 1 |
| Ahn, E; Kim, A; Kim, GT; Kim, Y; Lee, SG; So, MW | 1 |
| Nuki, G; Riches, P | 1 |
| Aoun, M; Chelala, D; Dfouni, A; Salloum, R; Sleilaty, G | 1 |
| Eliseev, MS; Novikova, AM | 1 |
| Jatuworapruk, K; Lertnawapan, R | 1 |
| Hsu, CN; Huang, YB; Lee, CT; Peng, YL; Tain, YL; Wen, YH; Yang, YH | 1 |
| Fan, M; Gu, J; Li, X; Liu, J; Schlesinger, N; Wu, X; Zhao, B | 1 |
| Barrientos-Regala, M; Castillo, RR; Macabeo, RA; Pestaño, NS; Punzalan, FER; Ramirez-Ragasa, R; Tumanan-Mendoza, B | 1 |
| Penserga, EG; Quilisadio, JEC; Salido, EO | 1 |
| Lagumdzija, D; Muratovic, S; Omerovic, N; Pehlivanovic, B; Skrbo, S; Ziga-Smajic, N | 1 |
| Abdelaziz, RR; Ibrahim, TM; Maresh, MM | 1 |
| Doi, Y; Fukae, S; Ikeda, S; Kawano, H; Koga, S; Maemura, K; Minami, T; Nakata, T; Tsuneto, A; Yonekura, T | 1 |
| Alqahtani, A; Balakumar, P; Dhanaraj, SA; Khan, NA; Mahadevan, N | 1 |
| Dronamraju, N; Erlandsson, F; Goldwater, R; Han, D; Johansson, S; Johnsson, E; Oscarsson, J; Parkinson, J; Stack, AG | 1 |
| Clebak, KT; Croad, JR; Morrison, A | 1 |
| Dronamraju, N; Erlandsson, F; Johansson, S; Johnsson, E; Parkinson, J; Stack, AG; Terkeltaub, R | 1 |
| De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Nuki, G; Perez-Ruiz, F; Ralston, SH; Robertson, M; Walters, M; Webster, J | 1 |
| Hill-McManus, D; Hughes, DA | 1 |
| Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB | 1 |
| Abe, Y; Fukumoto, Y; Hisatome, I; Hongou, M; Hoshide, S; Kario, K; Kasai, T; Kiuchi, M; Kiyosue, A; Kuga, H; Kuramochi, J; Miyazaki, S; Nishizawa, M; Ohtani, H; Tomita, F; Yasu, T | 1 |
| Cui, X; Geng, H; Jia, E; Jiang, Y; Li, B; Ma, W; Qiu, X; Wei, J; Xiao, M; Xiao, Y; Xie, J; Yao, X; Zhang, J; Zhang, Y; Zhong, L | 1 |
| Borghi, C; Desideri, G; Gerritsen, M; Giannattasio, C; Nurmohamed, MT; Rajzer, M; Tausche, AK | 1 |
| Ito, K; Kashiwagi, Y; Kimura, H; Nagoshi, T; Oi, Y; Takahashi, H; Tanaka, TD; Tanaka, Y; Yoshii, A; Yoshimura, M | 1 |
| Chertow, GM; Jalal, DI | 1 |
| Huang, X; Li, ZL; Ma, KL; Tang, DH; Wang, CY; Ye, YS; Yi, HK; Zhang, JW | 1 |
| Tausche, AK | 1 |
| Becce, F; Budzik, JF; Ducoulombier, V; Lefebvre, A; Pascart, T | 1 |
| Chen, W; Jin, Z; Wu, M; Zhang, H; Zhang, W; Zhao, D | 1 |
| Hosoya, T; Ishikawa, T; Takahashi, T; Taniguchi, T | 1 |
| Chen, J; Deng, Q; Guo, J; Xie, Q; Xie, S; Yu, Y; Zhang, S; Zhong, L | 1 |
| Coremans, C; Cullus, P; De Becker, B; Delporte, C; Dewachter, L; Franck, T; Hupkens, E; van Antwerpen, P; van de Borne, P; Zouaoui Boudjeltia, K | 1 |
| Li, H; Sun, J; Wang, M; Wen, C; Xie, Z; Zhang, M; Zhang, Y; Zhao, T | 1 |
| Downie, L; Riches, PL; Thomson, C | 1 |
| Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N | 2 |
| Azushima, K; Kanaoka, T; Kinguchi, S; Okami, N; Tamura, K; Tsukamoto, S; Uneda, K; Wakui, H; Yamada, T; Yamaji, T | 1 |
| Geng, H; Jia, E; Lin, F; Liu, S; Wang, Y; Zhang, J; Zhong, L; Zhu, H | 1 |
| Lee, YH; Song, GG | 1 |
| Kashiwagi, T; Sakai, Y; Yamada, T | 1 |
| Ishibashi, T; Kobayashi, A; Konno, I; Kunii, H; Machii, H; Miyamoto, T; Nakazato, K; Niizeki, T; Nozaki, N; Suzuki, S; Takeishi, Y; Tsuda, A; Tsuda, T; Yamaguchi, O; Yamaki, T; Yokokawa, T; Yoshihisa, A | 1 |
| Billington, K; Bursill, D; Dalbeth, N; Doyle, AJ; Gamble, GD; Horne, A; Latto, K; Mihov, B; Murdoch, R; Narang, R; Parshu Ram, T; Stamp, LK; Tan, P | 1 |
| Blake, KEG; Saag, JL; Saag, KG | 1 |
| Lin, F; Mao, Q; Sun, M; Wang, S; Zhang, B; Zhang, T; Zhao, J | 1 |
| He, Z; Li, M; Ma, G; Teng, W; Xia, Z; Zhai, X | 1 |
| Chang, TI; Han, SH; Jhee, JH; Joo, YS; Kang, SW; Kim, HW; Kim, JY; Park, JT; Roh, YH; Yoo, TH; Yun, HR | 1 |
| Eguchi, K; Fukumoto, Y; Ishizu, T; Kario, K; Kato, T; Node, K; Ohishi, M; Shiina, K; Takase, B; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Yoshida, H | 1 |
| Fairbanks, L; Gibson, T; Löffler, W | 1 |
| Hosoya, T; Iwasa, N; Kataoka, H; Kimura, K; Mochizuki, T; Nitta, K; Ohara, M; Tsuchiya, K; Tsuruta, Y; Yoshida, R | 1 |
| Aizawa, T; Chen, W; Fujita, R; Hagiwara, Y; Kanzaki, M; Li, Y; Ogawa, K; Suzuki, K; Takahashi, T; Tsuchiya, M; Yabe, Y; Yoshida, S | 1 |
| Chin-Kanasaki, M; Imamura-Uehara, Y; Kato, K; Kume, S; Kuwagata, S; Maegawa, H; Nakagawa, Y; Ohno, S; Takeda, N; Yamahara, K; Yasuda-Yamahara, M | 1 |
| Hamasaki, S; Inoue, T; Ishizu, T; Kato, T; Node, K; Tanaka, A; Toyoda, S; Ueda, S; Watarai, M; Yoshida, H | 1 |
| Becker, MA; Borer, JS; Castillo, M; Gorelick, PB; Gunawardhana, L; Hunt, B; Saag, KG; Whelton, A; White, WB | 1 |
| Gruber, F; Kossmeier, M; Leitner, S; Litschauer, B; Reichardt, B; Sibinovic, S; Weisshaar, S; Wolzt, M | 1 |
| Gu, M; Kong, W; Yu, X; Zhang, L; Zhu, Y; Zou, Y | 1 |
| Burianov, OA; Danyliuk, SV; Khimion, LV; Nayshtetik, IM; Rotova, SO; Smiyan, SI; Trofanchuk, VV | 1 |
| Chen, Y; Cheng, X; Cui, L; Dalbeth, N; He, Y; Hu, S; Ji, A; Li, C; Li, H; Liu, Z; Lu, J; Ma, L; Qi, H; Ran, Z; Sun, M; Terkeltaub, R; Wang, C; Xue, X; Yan, F; Yu, Q; Yuan, X | 1 |
| Cai, C; Chen, M; Cui, C; Lin, Z; Liu, H; Qin, H; Zheng, B; Zhu, Y | 1 |
| Bittleman, D; Coras, R; Dadpey, B; Guma, M; Hamilton, B; Lauro, K; Liu-Bryan, R; Mikuls, TR; Quehenberger, O; Reilly, SM; Terkeltaub, R; Thorisdottir, H | 1 |
| Bao, S; Bian, X; Dai, L; Huang, J; Ma, J; Yu, Q; Zhang, A | 1 |
| Deng, JH; Zhang, JX; Zhong, GW | 1 |
| Kobayashi, Y; Koide, Y; Matsunaga, K; Node, K; Saito, Y; Tanaka, A; Uchida, D; Ueyama, C; Yokota, N; Yoshida, H | 1 |
| Cao, Y; Deng, Y; Jiang, X; Li, C; Li, X; Lin, P; Ma, Y; Sun, F; Tao, Y; Wang, C; Yu, Q; Zhu, Y | 1 |
| Hou, C; Li, Y; Ren, J; Sha, W; Yao, M | 1 |
| Cai, Y; Cai, Z; Chen, T; Huang, X; Mi, X; Shui, G; Wang, F | 1 |
| Iguchi, T; Ishiguro, C; Kajiyama, K; Kimura, R; Nakazato, Y; Oniyama, Y; Sawada, S; Shida, H; Uyama, Y | 1 |
| Ghang, B; Jeong, W; Kim, J; Lee, J | 1 |
| Cao, B; Yang, N | 1 |
| Cui, J; Hou, J; Wang, W; Zhang, X | 1 |
| Haydar, SMA; Murray, N; Nicolaou, S; Ouellette, H; Saffarzadeh, M; Shojania, K | 1 |
| Lee, J; Min, J; Saag, KG; Shin, S; Terkeltaub, R | 1 |
| Douguchi, S; Hosoya, M; Katoh, M; Ofuchi, K; Osonoi, T; Saito, M | 1 |
| Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kohagura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N | 1 |
| Chang, YK; Choi, WJ; Hong, YA; Kim, SY; Park, CW; Yang, KJ | 1 |
| Tamura, K; Tsukamoto, SI; Wakui, H | 1 |
| Kawada, T | 1 |
| Bando, YK; Fujii, Y; Kadokami, T; Koide, H; Murohara, T; Node, K; Nomura, S; Saito, M; Sano, H; Tanaka, A; Teragawa, H; Ueda, T; Yoshida, H | 1 |
| Abdel Moneim, AE; Daabees, HG; Elagawany, M; Rashad, AY; Rostom, SAF; Shahin, M | 1 |
| Mironova, OI | 1 |
| Do, JY; Kang, SH; Kim, BY; Kim, GO; Son, EJ | 1 |
| Chen, H; Chen, L; Ding, R; Hu, X; Jiang, F; Li, X; Li, Y; Liu, K; Peng, Q; Wu, J; Xiong, T; Zhou, Y | 1 |
| Arima, H; Funakoshi, R; Iseki, K; Ishida, A; Kinjyo, K; Kochi, M; Kohagura, K; Nakamura, T; Ohya, Y; Sakima, A; Satoh, A; Tana, T; Yamazato, M; Zamami, R | 1 |
| Fujii, M; Fukuoka, T; Hirohata, S; Honma, K; Kakimoto, M; Kirihara, S; Kitamori, K; Nakayama, H; Ran, S; Sato, I; Watanabe, S; Yamamoto, S | 1 |
| Babkin, PA; Paronnikov, MV; Protoshchak, VV; Sleptsov, AV | 1 |
| Kim, AR; Lee, SG; So, MW | 1 |
| Inkong, P; Nata, N; Ninwisut, N; Satirapoj, B; Supasyndh, O | 1 |
65 review(s) available for uric acid and febuxostat
| Article | Year |
|---|---|
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Topics: Allopurinol; Amlodipine; Clinical Trials as Topic; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Losartan; Pyrazoles; Thiazoles; Treatment Outcome; Urate Oxidase; Uric Acid; Xanthine Oxidase | 2004 |
An update on the treatment options for gout and calcium pyrophosphate deposition.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Allopurinol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Chondrocalcinosis; Colchicine; Drug Combinations; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Multicenter Studies as Topic; Probenecid; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2005 |
New developments in clinically relevant mechanisms and treatment of hyperuricemia.
Topics: Febuxostat; Humans; Hyperuricemia; Prognosis; Thiazoles; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2006 |
Uricase and other novel agents for the management of patients with treatment-failure gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiazoles; Treatment Failure; Urate Oxidase; Uric Acid | 2007 |
Hyperuricemia and gout: new insights into pathogenesis and treatment.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Interleukin 1 Receptor Antagonist Protein; Thiazoles; Urate Oxidase; Uric Acid | 2007 |
Febuxostat.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Molecular Structure; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Uric Acid | 2008 |
Update on emerging urate-lowering therapies.
Topics: Allopurinol; Drug Discovery; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Thiazoles; United States; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2009 |
Approach to the treatment of hyperuricemia.
Topics: Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2009 |
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Topics: Allopurinol; Biotransformation; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Half-Life; Humans; Hyperuricemia; Thiazoles; Tissue Distribution; Uric Acid; Xanthine Dehydrogenase; Xanthine Oxidase | 2009 |
Gout therapeutics: new drugs for an old disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; Enzyme Inhibitors; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Thiazoles; United States; United States Food and Drug Administration; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2011 |
Crystal arthropathies: recognizing and treating "the gouch".
Topics: Allopurinol; Antimetabolites; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric Acid; Uricosuric Agents | 2010 |
[Treatment of gout].
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid; Uricosuric Agents | 2011 |
[Febuxostat].
Topics: Allopurinol; Enzyme Activation; Febuxostat; Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid; Xanthine Oxidase | 2011 |
A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Primary Health Care; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria.
Topics: Animals; Calcium Oxalate; Crystallization; Cystinuria; Drugs, Investigational; Febuxostat; Humans; Kidney; Kidney Calculi; Secondary Prevention; Thiazoles; Treatment Outcome; Uric Acid; Uricosuric Agents | 2011 |
[Gout - regardless of therapeutic options a "forgotten" disease].
Topics: Allopurinol; Arthritis, Gouty; Benzbromarone; Combined Modality Therapy; Cytokines; Europe; Febuxostat; Gout; Gout Suppressants; Guideline Adherence; Humans; Inflammasomes; Interleukin-1; Long-Term Care; Probenecid; Signal Transduction; Thiazoles; Uric Acid | 2011 |
Recent advances in management of gout.
Topics: Adrenal Cortex Hormones; Alcohol Drinking; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Ascorbic Acid; Colchicine; Comorbidity; Cryotherapy; Diet; Dose-Response Relationship, Drug; Febuxostat; Fructose; Gout; Gout Suppressants; Humans; Interleukin 1 Receptor Antagonist Protein; Polyethylene Glycols; Purines; Receptors, Interleukin-1; Recombinant Fusion Proteins; Thiazoles; Urate Oxidase; Uric Acid; Uricosuric Agents; Vitamins; Xanthine Oxidase | 2012 |
[Gout: an overview of available urate lowering therapies].
Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Guidelines as Topic; Humans; Organ Transplantation; Polyethylene Glycols; Thiazoles; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2012 |
Evaluation and treatment of gout as a chronic disease.
Topics: Arthritis, Gouty; Chronic Disease; Disease Progression; Evaluation Studies as Topic; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Male; Pain Measurement; Polyethylene Glycols; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Thiazoles; Treatment Outcome; Urate Oxidase; Uric Acid | 2012 |
Safety of urate-lowering therapies: managing the risks to gain the benefits.
Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; Thiazoles; Uric Acid | 2012 |
Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid | 2013 |
A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid | 2013 |
Treatment of calcium nephrolithiasis in the patient with hyperuricosuria.
Topics: Allopurinol; Biomarkers; Calcium Oxalate; Febuxostat; Humans; Indapamide; Kidney; Nephrolithiasis; Risk Factors; Treatment Outcome; Uric Acid; Uricosuric Agents | 2014 |
Allopurinol for chronic gout.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Probenecid; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid | 2014 |
Advances in pharmacotherapy for the treatment of gout.
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzbromarone; Clinical Trials, Phase III as Topic; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Probenecid; Thiazoles; Urate Oxidase; Uric Acid | 2015 |
[A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Uric Acid | 2014 |
Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2016 |
Pathogenesis and Clinical Management of Gouty Arthritis.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Gouty; Colchicine; Diet, Healthy; Febuxostat; Fluid Therapy; Gout Suppressants; Humans; Hyperuricemia; Inflammation; Interleukin 1 Receptor Antagonist Protein; Polyethylene Glycols; Smoking Cessation; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2015 |
Xanthine oxidoreductase and its inhibitors: relevance for gout.
Topics: Allopurinol; Animals; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hypoxanthine; Uric Acid; Xanthine Dehydrogenase | 2016 |
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Care Planning; Probenecid; Renal Insufficiency, Chronic; Uric Acid; Uricosuric Agents | 2017 |
Lesinurad: A Review in Hyperuricaemia of Gout.
Topics: Adult; Allopurinol; Drug Therapy, Combination; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Kidney; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2017 |
Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Topics: Adult; Allopurinol; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid | 2017 |
The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
Topics: Allopurinol; Blood Pressure; Enzyme Inhibitors; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2017 |
Uric Acid: The Unknown Uremic Toxin.
Topics: Allopurinol; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Kidney; Parenchymal Tissue; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Topics: Allopurinol; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Progression; Enzyme Inhibitors; Febuxostat; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Monosaccharide Transport Proteins; Nitriles; Oxidative Stress; Pyridines; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid; Xanthine Oxidase | 2018 |
Gout: state of the art after a decade of developments.
Topics: Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Xanthine Oxidase | 2019 |
Gout - An update of aetiology, genetics, co-morbidities and management.
Topics: Allopurinol; Chronic Disease; Comorbidity; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thioglycolates; Triazoles; Uric Acid | 2018 |
The Challenges of Approaching and Managing Gout.
Topics: Acetamides; Allopurinol; Antibodies, Monoclonal, Humanized; Colchicine; Diet Therapy; Febuxostat; Gout; Gout Suppressants; Humans; Medication Adherence; Patient Education as Topic; Phenylacetates; Polyethylene Glycols; Quality of Health Care; Rheumatology; Thioglycolates; Triazoles; Urate Oxidase; Uric Acid | 2019 |
The role of febuxostat in gout.
Topics: Biomarkers; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid | 2019 |
Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Topics: Allopurinol; Anti-Inflammatory Agents; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid | 2019 |
Painless gouty tophus in the nasal bridge: A case report and literature review.
Topics: Aged; Arthritis, Gouty; Biopsy, Fine-Needle; C-Reactive Protein; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Male; Nose; Prevalence; Tomography, X-Ray Computed; Uric Acid | 2019 |
Febuxostat administration for the prevention of tumour lysis syndrome: A meta-analysis.
Topics: Allopurinol; Animals; Febuxostat; Gout Suppressants; Humans; Tumor Lysis Syndrome; Uric Acid | 2019 |
Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis.
Topics: Disease Progression; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Renal Insufficiency, Chronic; Uric Acid | 2019 |
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Topics: Aged; Allopurinol; Asymptomatic Diseases; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2019 |
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Benzothiazoles; Drug Interactions; Febuxostat; Female; Gout; Humans; Hyperuricemia; Male; Uric Acid; Uricosuric Agents | 2020 |
Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies.
Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Heart Failure; Humans; Oxypurinol; Uric Acid; Xanthine Oxidase | 2020 |
Efficacy and safety of febuxostat for treatment of asymptomatic hyperuricemia among kidney transplant patients: A meta-analysis of observational studies.
Topics: Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Observational Studies as Topic; Treatment Outcome; Uric Acid | 2020 |
Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Humans; Hyperuricemia; Risk Assessment; Uric Acid | 2020 |
Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
Topics: Allopurinol; Bayes Theorem; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Randomized Controlled Trials as Topic; Uric Acid | 2020 |
Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome; Uric Acid | 2020 |
Changing paradigms in the management of gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid | 2020 |
Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2021 |
The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
Topics: Aged; Allopurinol; Biomarkers; Blood Pressure; Febuxostat; Female; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Uric Acid | 2020 |
Mechanistic insights into hyperuricemia-associated renal abnormalities with special emphasis on epithelial-to-mesenchymal transition: Pathologic implications and putative pharmacologic targets.
Topics: Animals; Biomarkers; Cytokines; Epithelial-Mesenchymal Transition; Febuxostat; Fibrosis; Gout Suppressants; Humans; Hyperuricemia; Inflammation Mediators; Kidney; Kidney Diseases; Oxidative Stress; Signal Transduction; Uric Acid | 2020 |
Gout: Rapid Evidence Review.
Topics: Adrenal Cortex Hormones; Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Obesity; Risk Factors; Sex Factors; Uric Acid | 2020 |
Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease.
Topics: Disease Progression; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Uric Acid | 2021 |
Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
Topics: Benzothiazoles; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Uricosuric Agents | 2021 |
The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
Topics: Allopurinol; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Randomized Controlled Trials as Topic; Uric Acid | 2021 |
The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2021 |
Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
Topics: Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; Network Meta-Analysis; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
Topics: Benzbromarone; Benzothiazoles; Febuxostat; Gout; Gout Suppressants; Humans; Network Meta-Analysis; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid; Uricosuric Agents | 2022 |
What's new on the front-line of gout pharmacotherapy?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Quality of Life; Uric Acid | 2022 |
Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Allopurinol; Bayes Theorem; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Research Progress of Natural Active Substances with Uric-Acid-Reducing Activity.
Topics: Allopurinol; Febuxostat; Humans; Hyperuricemia; Kidney; Uric Acid; Xanthine Oxidase | 2022 |
[Hyperuricemia and kidney damage in patients with cardiovascular disease: A review].
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Acid | 2023 |
90 trial(s) available for uric acid and febuxostat
| Article | Year |
|---|---|
Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
Topics: Adult; Area Under Curve; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Female; Humans; Liver; Male; Placebos; Purines; Thiazoles; Time Factors; Uric Acid; Xanthine Oxidase | 2004 |
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2005 |
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Uric Acid; Xanthine Oxidase | 2005 |
Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hypoxanthine; Male; Models, Biological; Thiazoles; Uric Acid; Xanthine; Xanthine Oxidase | 2006 |
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Biotransformation; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hypoxanthine; Male; Protein Binding; Sex Factors; Thiazoles; Uric Acid; Xanthine; Xanthine Oxidase; Young Adult | 2008 |
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid | 2008 |
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
Topics: Adult; Aged; Biomarkers; Clinical Trials, Phase II as Topic; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Joints; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2009 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Drug; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Hyperuricemia; Kidney Diseases; Male; Middle Aged; Obesity; Thiazoles; Treatment Outcome; United States; Uric Acid; Young Adult | 2010 |
Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.
Topics: Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Febuxostat; Female; Gout Suppressants; Humans; Hydrochlorothiazide; Male; Middle Aged; Thiazoles; Uric Acid; Xanthine Oxidase; Young Adult | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Schedule; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2010 |
Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
Topics: Adult; Aged; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Topics: Adult; Central Nervous System Diseases; Dental Enamel; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Japan; Kidney Diseases, Cystic; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Febuxostat; Female; Follow-Up Studies; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Oxypurinol; Renal Insufficiency; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase; Young Adult | 2011 |
Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Illinois; Male; Metabolic Diseases; Middle Aged; Obesity; Retrospective Studies; Sex Factors; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2012 |
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Liver Function Tests; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid | 2011 |
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
Topics: Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2012 |
Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Kidney Function Tests; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid | 2013 |
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial).
Topics: Aged; Albuminuria; Allopurinol; Arachidonic Acid; Blood Pressure; C-Reactive Protein; Cardiac Surgical Procedures; Cholesterol; Creatinine; Cystatin C; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Lipoproteins, LDL; Male; Middle Aged; Pulse Wave Analysis; Stroke Volume; Thiazoles; Uric Acid | 2013 |
Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones.
Topics: Adult; Allopurinol; Biomarkers; Calcium Oxalate; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Humans; Male; Middle Aged; Multidetector Computed Tomography; Thiazoles; Time Factors; Treatment Outcome; United States; Uric Acid; Urinary Calculi; Xanthine Oxidase | 2013 |
As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
Topics: Aged; Allopurinol; Biomarkers; Chronic Disease; Enzyme Inhibitors; Febuxostat; Germany; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Inflammation Mediators; Kidney; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pulse Wave Analysis; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Vascular Stiffness; Xanthine Oxidase | 2014 |
Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Dose-Response Relationship, Drug; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Longitudinal Studies; Male; Middle Aged; Prevalence; Thiazoles; Treatment Outcome; Uric Acid | 2014 |
The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Topics: Administration, Oral; Biomarkers; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Japan; Kidney; Prospective Studies; Renal Insufficiency, Chronic; Research Design; Risk Factors; Severity of Illness Index; Tablets; Thiazoles; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid | 2014 |
An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Topics: Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Remission Induction; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2014 |
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Topics: Adult; Aged; Colchicine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Thioglycolates; Triazoles; Uric Acid | 2014 |
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Topics: Aged; Albuminuria; Allopurinol; C-Reactive Protein; Cardiac Surgical Procedures; Cholesterol; Creatinine; Cystatin C; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Renal Insufficiency, Chronic; Triglycerides; Uric Acid | 2015 |
Effects of febuxostat on serum urate level in Japanese hyperuricemia patients.
Topics: Adult; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Prevalence; Treatment Outcome; Uric Acid | 2015 |
Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Albuminuria; beta 2-Microglobulin; Enzyme Inhibitors; Fatty Acid-Binding Proteins; Febuxostat; Female; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Uric Acid; Xanthine Oxidase | 2015 |
Comparison of pharmacokinetics and uric acid lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects.
Topics: Adult; Area Under Curve; Biomarkers; Cross-Over Studies; Down-Regulation; Enzyme Inhibitors; Febuxostat; Gout Suppressants; Half-Life; Healthy Volunteers; Humans; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Republic of Korea; Therapeutic Equivalency; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase; Young Adult | 2015 |
Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2015 |
A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Topics: Administration, Oral; Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Time Factors; Treatment Outcome; Uric Acid | 2015 |
Combination Therapies of Diacerein and Febuxostat Inhibit IL-1β Responses and Improve Clinical Symptoms in Patients With Refractory Gout.
Topics: Adult; Anthraquinones; Anti-Inflammatory Agents; C-Reactive Protein; Case-Control Studies; Drug Therapy, Combination; Etoricoxib; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Interleukin-18; Interleukin-1beta; Male; Middle Aged; Prospective Studies; Pyridines; Sulfones; Treatment Outcome; Uric Acid | 2017 |
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout Suppressants; Hematologic Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Risk Factors; Tumor Lysis Syndrome; Uric Acid; Young Adult | 2015 |
Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
Topics: Administration, Oral; Adult; Alleles; Allopurinol; China; Febuxostat; Female; Gout; Gout Suppressants; HLA-B Antigens; Humans; Hyperuricemia; Male; Middle Aged; Treatment Outcome; Uric Acid | 2016 |
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia.
Topics: Aged; Aged, 80 and over; Brain Diseases; Cardiovascular Diseases; Cause of Death; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Renal Insufficiency; Research Design; Single-Blind Method; Treatment Outcome; Uric Acid | 2017 |
Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Neoplasms; Thiazoles; Tumor Lysis Syndrome; Uric Acid; Xanthine Oxidase; Young Adult | 2016 |
Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Carotid Artery, Common; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Female; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Risk Factors; Uric Acid; Xanthine Oxidase; Young Adult | 2016 |
Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia.
Topics: Aged; Benzbromarone; Cross-Over Studies; Drug Therapy, Combination; Febuxostat; Female; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Treatment Outcome; Uric Acid | 2017 |
New urate depositions on dual-energy computed tomography in gouty arthritis during urate-lowering therapy.
Topics: Acute Disease; Adult; Allopurinol; Arthritis, Gouty; Biomarkers; C-Reactive Protein; Febuxostat; Female; Foot Joints; Gout Suppressants; Humans; Male; Middle Aged; Statistics, Nonparametric; Tomography, X-Ray Computed; Uric Acid | 2017 |
Effect of Febuxostat on the Endothelial Dysfunction in Hemodialysis Patients: A Randomized, Placebo-Controlled, Double-Blinded Study.
Topics: Administration, Oral; Adult; Alanine Transaminase; Arginine; Aspartate Aminotransferases; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Febuxostat; Female; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Pancytopenia; Placebos; Prospective Studies; Renal Dialysis; Risk Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2017 |
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
Topics: Creatinine; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid | 2017 |
Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
Topics: Adult; Aged; Anti-Inflammatory Agents; Antioxidants; Cardiovascular Diseases; Cross-Over Studies; Febuxostat; Female; Humans; Hyperuricemia; Male; Middle Aged; Nitriles; Pyridines; Treatment Outcome; Uric Acid | 2017 |
Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Joints; Magnetic Resonance Imaging; Male; Middle Aged; Synovitis; Treatment Outcome; Uric Acid | 2017 |
Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Incidence; Male; Middle Aged; Prospective Studies; Symptom Flare Up; Uric Acid | 2018 |
Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; North America; Proof of Concept Study; Prospective Studies; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2017 |
Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial.
Topics: Adult; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Dosage Calculations; Drug Monitoring; Febuxostat; Gout; Gout Suppressants; Humans; Male; Medication Therapy Management; Middle Aged; Practice Guidelines as Topic; Treatment Outcome; United States; United States Department of Veterans Affairs; Uric Acid; Veterans Health | 2018 |
Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis.
Topics: Arthritis, Gouty; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diastole; Febuxostat; Female; Homeostasis; Humans; Hyperuricemia; Insulin; Male; Metabolic Syndrome; Middle Aged; Systole; Uric Acid | 2018 |
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers.
Topics: Adult; Area Under Curve; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Febuxostat; Healthy Volunteers; Humans; Male; Middle Aged; Naphthalenes; Propionates; Pyridines; Renal Elimination; Single-Blind Method; Uric Acid; Young Adult | 2019 |
Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
Topics: Aged; Alpha-Globulins; Benzbromarone; Febuxostat; Female; Glomerular Filtration Rate; Hemoglobins; Humans; Hyperuricemia; Kidney Calculi; Male; Middle Aged; Pilot Projects; Prospective Studies; Renal Insufficiency, Chronic; Uric Acid; Uricosuric Agents | 2018 |
Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Topics: Administration, Oral; Adult; Aged; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Thioglycolates; Time Factors; Treatment Outcome; Triazoles; Uric Acid; Uricosuric Agents; Young Adult | 2018 |
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Colchicine; Cough; Creatinine; Delayed-Action Preparations; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; gamma-Glutamyltransferase; Glomerular Filtration Rate; Gout; Gout Suppressants; Headache; Humans; Hypertension; Male; Middle Aged; Naproxen; Nasopharyngitis; Renal Insufficiency, Chronic; Respiratory Tract Infections; Severity of Illness Index; Treatment Outcome; Uric Acid | 2019 |
The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Treatment Outcome; Uric Acid | 2018 |
Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Male; Prospective Studies; Uric Acid | 2019 |
Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
Topics: Benzbromarone; Biomarkers; China; Dose-Response Relationship, Drug; Febuxostat; Follow-Up Studies; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidney; Male; Middle Aged; Prospective Studies; Treatment Outcome; Uric Acid; Uricosuric Agents | 2019 |
Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Topics: Aged; Antioxidants; Biomarkers; Cross-Over Studies; Down-Regulation; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Nitriles; Pyridines; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2020 |
Severe Hypouricemia Impairs Endothelium-Dependent Vasodilatation and Reduces Blood Pressure in Healthy Young Men: A Randomized, Placebo-Controlled, and Crossover Study.
Topics: Adult; Blood Pressure; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Febuxostat; Humans; Male; Microvessels; Severity of Illness Index; Urate Oxidase; Uric Acid; Vasodilation; Xanthine Oxidase; Young Adult | 2019 |
A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.
Topics: Adult; Aged; Benzothiazoles; Double-Blind Method; Febuxostat; Gout; Humans; Hyperuricemia; Japan; Male; Middle Aged; Treatment Outcome; Uric Acid; Uricosuric Agents | 2020 |
Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Carotid Artery Diseases; Carotid Intima-Media Thickness; Disease Progression; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Single-Blind Method; Uric Acid | 2020 |
Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
Topics: Adiponectin; Aged; Arginine; Benzbromarone; Cross-Over Studies; Endothelium, Vascular; Febuxostat; Female; Gout Suppressants; Humans; Hyperemia; Hyperuricemia; Male; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Treatment Outcome; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2020 |
Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
Topics: Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Therapy, Combination; Enzyme Inhibitors; Febuxostat; Female; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Naphthalenes; Propionates; Pyridines; Treatment Outcome; United States; Uric Acid; Uricosuric Agents; Young Adult | 2021 |
Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
Topics: Aged; Albuminuria; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; Follow-Up Studies; Glomerular Filtration Rate; Gout Suppressants; Humans; Male; Middle Aged; Naphthalenes; Propionates; Prospective Studies; Pyridines; Treatment Outcome; Uric Acid | 2021 |
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Denmark; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Male; Prospective Studies; Sweden; Treatment Outcome; United Kingdom; Uric Acid | 2020 |
Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
Topics: Febuxostat; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Nitriles; Pyridines; Treatment Outcome; Uric Acid | 2021 |
Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Single-Blind Method; Symptom Flare Up; Treatment Outcome; Uric Acid | 2021 |
Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study.
Topics: Adult; Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Pulse Wave Analysis; Risk Factors; Thiazoles; Treatment Outcome; Uric Acid | 2022 |
Acute effects of hypouricemia on endothelium, oxidative stress, and arterial stiffness: A randomized, double-blind, crossover study.
Topics: Adult; Aged; Blood Pressure; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Febuxostat; Female; Forearm; Gout Suppressants; Humans; Laser-Doppler Flowmetry; Male; Middle Aged; Oxidative Stress; Uric Acid; Vascular Stiffness | 2021 |
Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial.
Topics: Aged; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2022 |
Effect of alkalized urine on renal calculi in patients with gout: a protocol for a placebo-controlled, double-blinded randomized controlled trial.
Topics: Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Kidney Calculi; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid | 2021 |
Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial.
Topics: Allopurinol; Febuxostat; Heart Failure; Humans; Hyperuricemia; Uric Acid | 2021 |
Intensive Serum Urate Lowering With Oral Urate-Lowering Therapy for Erosive Gout: A Randomized Double-Blind Controlled Trial.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Quality of Life; Treatment Outcome; Uric Acid | 2022 |
Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial.
Topics: Combined Modality Therapy; Contrast Media; Coronary Angiography; Coronary Disease; Creatinine; Febuxostat; Fluid Therapy; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Lipocalin-2; Percutaneous Coronary Intervention; Treatment Outcome; Uric Acid | 2022 |
Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE study.
Topics: Ankle Brachial Index; Atherosclerosis; Awards and Prizes; Carotid Artery Diseases; Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Prospective Studies; Pulse Wave Analysis; Uric Acid; Vascular Stiffness; Xanthine Oxidase | 2022 |
Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.
Topics: Creatinine; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Proteinuria; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial.
Topics: Adult; Awards and Prizes; Carotid Artery Diseases; Carotid Intima-Media Thickness; Febuxostat; Humans; Hyperuricemia; Uric Acid | 2022 |
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid | 2022 |
C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study.
Topics: Atherosclerosis; C-Reactive Protein; Febuxostat; Female; Humans; Hyperuricemia; Inflammation; Male; Treatment Outcome; Uric Acid | 2023 |
Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Prospective Studies; Treatment Outcome; Uric Acid | 2022 |
Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study.
Topics: Awards and Prizes; Blood Pressure; Carotid Intima-Media Thickness; Febuxostat; Humans; Hyperuricemia; Uric Acid; Xanthine Oxidase | 2022 |
A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia.
Topics: Drug Interactions; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2023 |
Simiao pill inhibits epithelial mesenchymal transition in a mouse model of chronic hyperuricemic nephropathy by inhibiting NLRP3 inflammasome activation.
Topics: Actins; Animals; Cadherins; Caspases; Disease Models, Animal; Epithelial-Mesenchymal Transition; Febuxostat; Fibronectins; Hyperuricemia; Inflammasomes; Interleukin-18; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Renal Insufficiency, Chronic; Uric Acid; Vimentin | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial.
Topics: Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up; Treatment Outcome; Uric Acid | 2023 |
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Topics: Aged; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2023 |
Effect of febuxostat on the level of malondialdehyde-modified low-density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study.
Topics: Carotid Artery Diseases; Cholesterol, LDL; Febuxostat; Humans; Hyperuricemia; Malondialdehyde; Oxidative Stress; Uric Acid | 2023 |
A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia.
Topics: Colchicine; East Asian People; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Male; Treatment Outcome; Uric Acid; Uricosuric Agents | 2023 |
Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.
Topics: Benzbromarone; Febuxostat; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2023 |
Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease.
Topics: C-Reactive Protein; Febuxostat; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Acid; Vascular Diseases | 2023 |
167 other study(ies) available for uric acid and febuxostat
| Article | Year |
|---|---|
Determination of plasma purine nucleoside phosphorylase activity by high-performance liquid chromatography.
Topics: Adult; Aged; Asthma; Calibration; Chromatography, High Pressure Liquid; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypoxanthine; Hypoxanthines; Inosine; Male; Middle Aged; Purine-Nucleoside Phosphorylase; Thiazoles; Uric Acid; Xanthine Oxidase | 1995 |
Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees.
Topics: Administration, Oral; Allopurinol; Animals; Dose-Response Relationship, Drug; Febuxostat; Female; Gout; Macaca mulatta; Male; Pan troglodytes; Thiazoles; Uric Acid; Xanthine; Xanthine Oxidase; Xanthines | 1993 |
Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents.
Topics: Allantoin; Allopurinol; Animals; Cattle; Febuxostat; Gout Suppressants; Male; Mice; Mice, Inbred ICR; Rats; Rats, Sprague-Dawley; Thiazoles; Uric Acid; Xanthine Dehydrogenase; Xanthine Oxidase | 1993 |
A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.
Topics: Allantoin; Allopurinol; Animals; Enzyme Inhibitors; Febuxostat; Kidney Calculi; Male; Rats; Rats, Inbred Strains; Thiazoles; Uric Acid; Xanthine; Xanthine Oxidase | 1999 |
Febuxostat--treatment for hyperuricemia and gout?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric Acid; Xanthine Oxidase | 2005 |
Gout's not just for the gluttonous.
Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Risk Factors; Sex Factors; Socioeconomic Factors; Thiazoles; Uric Acid | 2006 |
Case 8: initiation of urate-lowering therapy for standard advanced gout.
Topics: Arthritis, Gouty; Febuxostat; Humans; Male; Middle Aged; Oxypurinol; Thiazoles; Uric Acid; Uricosuric Agents | 2006 |
Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
Topics: Animals; Blood Pressure; Febuxostat; Follow-Up Studies; Gout Suppressants; Hypertension, Renal; Hyperuricemia; Kidney Glomerulus; Male; Oxonic Acid; Rats; Rats, Sprague-Dawley; Renal Circulation; Thiazoles; Uric Acid; Xanthine Oxidase | 2008 |
Febuxostat: a viewpoint by H. Ralph Schumacher Jr and Lan X. Chen.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid | 2008 |
Febuxostat : a viewpoint by Naomi Schlesinger.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid | 2008 |
Febuxostat : a viewpoint by N. Lawrence Edwards.
Topics: Administration, Oral; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid | 2008 |
Gout management: let's get it right this time.
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Drug Evaluation; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Uric Acid; Xanthine Oxidase | 2008 |
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid | 2009 |
New gout treatment approved.
Topics: Administration, Oral; Drug Approval; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; United States; United States Food and Drug Administration; Uric Acid; Xanthine Oxidase | 2009 |
Gout Study Group: update on hyperuricemia and gout.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diet; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Life Style; Prednisone; Prevalence; Thiazoles; United States; Uric Acid | 2009 |
The current state of care in gout: Addressing the need for better understanding of an ancient disease.
Topics: Acute Disease; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Chronic Disease; Colchicine; Comorbidity; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Patient Education as Topic; Quality of Life; Risk Factors; Thiazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2010 |
Treatment of gout.
Topics: Aged; Allopurinol; Australia; Colchicine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Febuxostat; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidney Diseases; Male; Patient Compliance; Practice Guidelines as Topic; Prednisolone; Renal Dialysis; Thiazoles; Uric Acid | 2011 |
Febuxostat efficacy in allopurinol-resistant tophaceous gout.
Topics: Allopurinol; Dose-Response Relationship, Drug; Drug Resistance; Febuxostat; Female; Gout; Gout Suppressants; Humans; Thiazoles; Treatment Failure; Treatment Outcome; Uric Acid; Young Adult | 2011 |
Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
Topics: Aged; Aged, 80 and over; Allopurinol; Drug Monitoring; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Thiazoles; Uric Acid | 2011 |
Catastrophic axial gout causing paraplegia in a patient with glycogen storage disease.
Topics: Adult; Catastrophic Illness; Drug Therapy, Combination; Febuxostat; Glycogen Storage Disease Type I; Gout; Gout Suppressants; Humans; Magnetic Resonance Imaging; Male; Obesity, Morbid; Paraplegia; Prednisone; Probenecid; Radiography; Synovial Fluid; Thiazoles; Uric Acid | 2011 |
Casebook consults: improving outcomes in gout (multimedia activity).
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Long-Term Care; Medication Adherence; Referral and Consultation; Thiazoles; Uric Acid | 2012 |
Adherence to uric acid treatment guidelines in a rheumatology clinic.
Topics: Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Guideline Adherence; Humans; Male; Middle Aged; Probenecid; Retrospective Studies; Thiazoles; Treatment Outcome; Uric Acid | 2012 |
Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment.
Topics: Aged; Aged, 80 and over; Biomarkers; Drug Monitoring; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Dialysis; Thiazoles; Time Factors; Treatment Outcome; Uric Acid | 2013 |
[Case presentation--tophaceous gout].
Topics: Aged, 80 and over; Arthritis, Gouty; Drug Therapy, Combination; Febuxostat; Female; Follow-Up Studies; Gout Suppressants; Hand Deformities, Acquired; Humans; Hyperuricemia; Mobility Limitation; Thiazoles; Uric Acid | 2012 |
Italian Society of Rheumatology recommendations for the management of gout.
Topics: Adrenal Cortex Hormones; Advisory Committees; Alcoholic Beverages; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Combined Modality Therapy; Dairy Products; Disease Management; Evidence-Based Medicine; Febuxostat; Female; Fructose; Gout; Humans; Italy; Male; Risk Factors; Smoking; Societies, Medical; Thiazoles; Uric Acid | 2013 |
Cost-effectiveness of febuxostat in chronic gout.
Topics: Cost-Benefit Analysis; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Reproducibility of Results; Thiazoles; Uric Acid | 2014 |
Pegloticase for treatment of tophaceous polyarticular gout.
Topics: Adult; Arthritis, Gouty; Febuxostat; Gout Suppressants; Humans; Male; Polyethylene Glycols; Thiazoles; Urate Oxidase; Uric Acid | 2013 |
Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Enzyme Inhibitors; Febuxostat; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Uric Acid | 2014 |
CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
Topics: Allopurinol; Comorbidity; Disease Management; Drug Administration Schedule; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medication Adherence; Primary Health Care; Risk Factors; Severity of Illness Index; Thiazoles; United States; Uric Acid | 2014 |
Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
Topics: Adult; Aged; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Thiazoles; Uric Acid; Xanthine Oxidase | 2014 |
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study.
Topics: Aged; Allopurinol; Black or African American; Evaluation Studies as Topic; Febuxostat; Female; Focus Groups; Gout; Gout Suppressants; Health Knowledge, Attitudes, Practice; Humans; Male; Medication Adherence; Middle Aged; Thiazoles; Uric Acid | 2014 |
Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Comparative Effectiveness Research; Drug Administration Schedule; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Logistic Models; Male; Middle Aged; Retrospective Studies; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2014 |
Anakinra treatment in patients with gout and type 2 diabetes.
Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Blood Glucose; Carbamates; Colchicine; Diabetes Mellitus, Type 2; Febuxostat; Glycated Hemoglobin; Gout; Gout Suppressants; Humans; Hyperuricemia; Hypoglycemic Agents; Insulin; Interleukin 1 Receptor Antagonist Protein; Metformin; Middle Aged; Piperidines; Treatment Outcome; Uric Acid | 2015 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypertension; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Uric Acid; Uricosuric Agents; Urolithiasis | 2014 |
A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.
Topics: Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Nitriles; Pyridines; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2014 |
Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction.
Topics: Aged; Blood Pressure; Dose-Response Relationship, Drug; Endpoint Determination; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Male; Middle Aged; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2014 |
Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Disease Progression; Drug Substitution; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Treatment Outcome; Uric Acid | 2014 |
Adherence and persistence to urate-lowering therapies in the Irish setting.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Databases, Factual; Febuxostat; Female; Gout; Gout Suppressants; Humans; Ireland; Male; Medication Adherence; Middle Aged; Retrospective Studies; Sex Factors; Uric Acid; Young Adult | 2016 |
The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Death; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Gastroesophageal Reflux; Gout Suppressants; Liver; Lung; Lung Injury; Male; Mice, Inbred C57BL; Necrosis; Neutrophil Infiltration; Peritoneum; Peritonitis; Thiazoles; Uric Acid; Xanthine Oxidase | 2015 |
Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
Topics: Aged; Allopurinol; Antineoplastic Agents; Creatinine; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Hematologic Neoplasms; Humans; Hypoxanthine; Male; Middle Aged; Pilot Projects; Prospective Studies; Thiazoles; Tumor Lysis Syndrome; Uric Acid; Xanthine; Xanthine Oxidase | 2014 |
Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.
Topics: Allopurinol; Chronic Disease; Cost-Benefit Analysis; Febuxostat; Gout; Gout Suppressants; Humans; Markov Chains; Thiazoles; Uric Acid | 2015 |
Characteristics and management of gout patients in Europe: data from a large cohort of patients.
Topics: Adult; Allopurinol; Cohort Studies; Comorbidity; Cross-Sectional Studies; Europe; Febuxostat; Female; France; Gout; Gout Suppressants; Greece; Humans; Male; Middle Aged; Obesity; Patient Compliance; Thiazoles; Uric Acid | 2015 |
Effects of Febuxostat on Oxidative Stress.
Topics: Adult; Aged; Allopurinol; Creatinine; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Oxidative Stress; Reactive Oxygen Species; Uric Acid | 2015 |
Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Topics: Aged; Allopurinol; Cohort Studies; Cost-Benefit Analysis; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Managed Care Programs; Medicare; Reference Values; Retrospective Studies; Severity of Illness Index; Treatment Outcome; United States; Uric Acid | 2015 |
The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Topics: Animals; Apoptosis; Choline Deficiency; Cytoprotection; Diet, High-Fat; Enzyme Inhibitors; Febuxostat; Gout Suppressants; Hyperuricemia; Liver; Liver Cirrhosis, Experimental; Methionine; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Thiazoles; Uric Acid; Xanthine Oxidase | 2015 |
Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Carotid Artery Thrombosis; Case-Control Studies; Cell-Derived Microparticles; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Interleukin-6; Male; Middle Aged; Uric Acid; Xanthine Oxidase | 2015 |
Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
Topics: Aged; Allopurinol; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Thyrotropin; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid; Xanthine Dehydrogenase | 2015 |
Febuxostat in the management of gout: a cost-effectiveness analysis.
Topics: Adult; Aged; Allopurinol; Cost-Benefit Analysis; Disease Management; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; United States; Uric Acid | 2016 |
A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.
Topics: Adult; Aged; Allopurinol; Comparative Effectiveness Research; Drug Monitoring; Drug Substitution; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; United States; Uric Acid; Xanthine Oxidase | 2015 |
Xanthine oxidoreductase activation is implicated in the onset of metabolic arthritis.
Topics: Adipose Tissue; Animals; Apoptosis; Carrier Proteins; Chondrocytes; Diet, High-Fat; Enzyme Activation; Enzyme Inhibitors; Febuxostat; Hyperuricemia; Inflammasomes; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type II; NLR Family, Pyrin Domain-Containing 3 Protein; Osteoarthritis; Osteophyte; RNA, Messenger; Synovial Membrane; Uric Acid; Xanthine Dehydrogenase | 2016 |
[Drug reduction of uric acid not just when symptoms appear].
Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Gout; Humans; Hyperuricemia; Uric Acid | 2016 |
Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Cost-Benefit Analysis; Febuxostat; Female; Gout; Gout Suppressants; Health Care Costs; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Uric Acid | 2016 |
Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
Topics: Aged; Allopurinol; Blood Pressure; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Humans; Hypertension; Hyperuricemia; Kidney; Male; Middle Aged; Renin-Angiotensin System; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2016 |
Effects of urate-lowering agents on arrhythmia vulnerability in post-infarcted rat hearts.
Topics: Animals; Arrhythmias, Cardiac; Febuxostat; GAP-43 Protein; Male; Myocardial Infarction; Myocardium; Nerve Growth Factor; Rats; Rats, Wistar; Superoxides; Tyrosine 3-Monooxygenase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2016 |
Febuxostat for Asymptomatic Hyperuricemia in CKD.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid; Xanthine Oxidase | 2016 |
Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2016 |
In Reply to 'Febuxostat for Asymptomatic Hyperuricemia in CKD' and 'Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia'.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2016 |
[Extreme gout can get out of hand].
Topics: Arthritis, Gouty; China; Disease Progression; Febuxostat; Germany; Gout Suppressants; Hand Deformities, Acquired; Humans; Male; Middle Aged; Uric Acid | 2016 |
Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
Topics: Computer Simulation; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Models, Biological; Renal Insufficiency, Chronic; Uric Acid; Xanthine; Xanthine Oxidase | 2016 |
The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
Topics: Adult; Aged; Allopurinol; Budgets; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Health Care Costs; Humans; Male; Managed Care Programs; Middle Aged; Pharmaceutical Services; Renal Insufficiency, Chronic; United States; Uric Acid; Young Adult | 2016 |
Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2016 |
Tophaceous Gout in an Anorectic Patient Visualized by Dual Energy Computed Tomography (DECT).
Topics: Absorptiometry, Photon; Allopurinol; Anorexia Nervosa; Biomarkers; Biopsy; Colchicine; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Middle Aged; Patient Compliance; Predictive Value of Tests; Sensitivity and Specificity; Urate Oxidase; Uric Acid | 2016 |
Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.
Topics: Acute Disease; Aged; Allopurinol; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Uric Acid; Xanthine Oxidase | 2017 |
Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout.
Topics: Adult; Aged; C-Reactive Protein; Febuxostat; Female; Gout; Gout Suppressants; Humans; Insulin Resistance; Male; Middle Aged; Uric Acid; Young Adult | 2017 |
Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
Topics: Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Drug Monitoring; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Retrospective Studies; Rheumatology; Tennessee; Uric Acid; Veterans; Xanthine Oxidase | 2017 |
A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Topics: Adult; Allopurinol; Asian People; Benzbromarone; Biomarkers; China; Drug Dosage Calculations; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome; Uric Acid | 2017 |
Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Topics: Aged; Allopurinol; Biomarkers; Drug Substitution; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Medical Audit; Medication Adherence; Practice Guidelines as Topic; Probenecid; Retrospective Studies; Rheumatology; Time Factors; Treatment Outcome; Uric Acid | 2017 |
Ameliorative effects of sildenafil and/or febuxostat on doxorubicin-induced nephrotoxicity in rats.
Topics: Animals; Apoptosis; Caspase 3; Creatinine; Cytoprotection; Doxorubicin; Drug Interactions; Febuxostat; Gene Expression Regulation, Enzymologic; Glutathione; Kidney; Male; Malondialdehyde; Oxidative Stress; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Tumor Necrosis Factor-alpha; Urea; Uric Acid | 2017 |
Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes.
Topics: Adult; Angiotensin II; Blood Pressure; Case-Control Studies; Diabetes Mellitus, Type 1; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperglycemia; Interleukin-18; Linear Models; Male; Nitric Oxide; Nitroglycerin; Renal Plasma Flow, Effective; Renin-Angiotensin System; Uric Acid; Vascular Stiffness; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Young Adult | 2017 |
Management of Gout and Hyperuricemia in CKD.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Diet Therapy; Disease Management; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Symptom Flare Up; Treatment Outcome; Uric Acid | 2017 |
Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Uric Acid | 2017 |
[Effect of febuxostat on epithelial-to-mesenchymal transition of kidney tubules, serum interleukin-6 and transforming growth factor β(1) in hyperuricemic rats].
Topics: Animals; Antigens, CD; Cadherins; Chalcone; Creatinine; Drugs, Chinese Herbal; Epithelial-Mesenchymal Transition; Febuxostat; Gout Suppressants; Hyperuricemia; Interleukin-6; Kidney Tubules; Male; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta; Transforming Growth Factor beta1; Uric Acid | 2017 |
Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Comorbidity; Febuxostat; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuricemia; Japan; Longitudinal Studies; Male; Middle Aged; Prevalence; Renal Agents; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Sex Distribution; Treatment Outcome; Uric Acid; Vascular Diseases; Young Adult | 2017 |
Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database.
Topics: Allopurinol; Benzbromarone; Databases, Factual; Febuxostat; Gout; Gout Suppressants; Humans; Republic of Korea; Uric Acid | 2018 |
Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients.
Topics: Adult; Aged; Febuxostat; Female; Follow-Up Studies; Humans; Hyperuricemia; Male; Middle Aged; Nitriles; Prospective Studies; Pyridines; Renal Dialysis; Uric Acid; Uricosuric Agents | 2017 |
Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.
Topics: Computer Simulation; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Models, Biological; Risk Assessment; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid; Xanthine Oxidase | 2018 |
Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies.
Topics: Adolescent; Age Factors; Allopurinol; Antineoplastic Agents; Biomarkers; Child; Child, Preschool; Creatinine; Down-Regulation; Enzyme Inhibitors; Febuxostat; Female; Hematologic Neoplasms; Humans; Induction Chemotherapy; Japan; Male; Retrospective Studies; Risk Factors; Treatment Outcome; Tumor Lysis Syndrome; Uric Acid; Xanthine Oxidase | 2017 |
Population Pharmacodynamic Analysis of Uric Acid-Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals.
Topics: Aged; Electronic Health Records; Febuxostat; Female; Humans; Male; Middle Aged; Models, Biological; Uric Acid | 2018 |
Evaluation of the Effectiveness of Xanthine Oxidoreductase Inhibitors on Haemodialysis Patients using a Marginal Structural Model.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Incidence; Kidney Failure, Chronic; Male; Models, Structural; Prognosis; Renal Dialysis; Risk Factors; Survival Rate; Uric Acid; Xanthine Dehydrogenase | 2017 |
Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Topics: Aged; Allopurinol; Benzbromarone; Cohort Studies; Disease Progression; Drug Monitoring; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Incidence; Male; Middle Aged; Renal Insufficiency, Chronic; Taiwan; Uric Acid; Uricosuric Agents | 2018 |
Efficacy and Safety of Febuxostat in Kidney Transplant Patients.
Topics: Adult; Aged; Biomarkers; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Male; Medical Records; Middle Aged; Retrospective Studies; Risk Factors; Seoul; Treatment Outcome; Uric Acid; Xanthine Oxidase; Young Adult | 2018 |
Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease.
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Febuxostat; Foot Deformities, Acquired; Gout; Gout Suppressants; Humans; Male; Probenecid; Renal Insufficiency, Chronic; Severity of Illness Index; Treatment Outcome; Uric Acid | 2018 |
Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Humans; Hyperuricemia; Models, Theoretical; Precision Medicine; Thioglycolates; Triazoles; Uric Acid; Uricosuric Agents | 2018 |
Chronic Disease Approaches Needed to Curb Gout's Growing Burden.
Topics: Allopurinol; Chronic Disease; Diet; Drug Combinations; Febuxostat; Gout; Gout Suppressants; Healthy Lifestyle; Humans; Patient Education as Topic; Practice Guidelines as Topic; Purines; Thioglycolates; Triazoles; Uric Acid | 2018 |
The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Topics: Adult; Aged; Allopurinol; Blood Pressure; Febuxostat; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Uric Acid | 2018 |
Surprising safety outcomes of urate-lowering therapy.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid | 2018 |
Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Down-Regulation; Drug Resistance; Drug Substitution; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Odds Ratio; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Uric Acid; Young Adult | 2018 |
Evaluation of a pharmacokinetic-pharmacodynamic model for hypouricaemic effects of febuxostat using datasets obtained from real-world patients.
Topics: Adult; Aged; Body Weight; Comorbidity; Datasets as Topic; Diabetes Mellitus; Dose-Response Relationship, Drug; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Models, Biological; Sodium Potassium Chloride Symporter Inhibitors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2018 |
Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.
Topics: Aged; Arthritis, Gouty; Creatinine; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Uric Acid | 2018 |
Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
Topics: Aged; Allopurinol; Cohort Studies; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Probenecid; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Severity of Illness Index; Uric Acid; Uricosuric Agents | 2018 |
Auricle Pain Due to Tophi.
Topics: Arthritis, Gouty; Ear Auricle; Febuxostat; Gout Suppressants; Humans; Male; Middle Aged; Pain; Uric Acid | 2019 |
Cardiovascular Safety of Febuxostat.
Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid | 2018 |
Cardiovascular Safety of Febuxostat.
Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid | 2018 |
Cardiovascular Safety of Febuxostat.
Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid | 2018 |
Cardiovascular Safety of Febuxostat.
Topics: Cardiovascular System; Febuxostat; Gout; Humans; Thiazoles; Treatment Outcome; Uric Acid | 2018 |
Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet?
Topics: Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
Topics: Allopurinol; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; Febuxostat; Gout; Gout Suppressants; Health Care Costs; Humans; Medication Adherence; Models, Biological; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Thioglycolates; Treatment Outcome; Triazoles; United Kingdom; Uric Acid | 2018 |
[A case of gout secondary to primary myelofibrosis].
Topics: Arthritis, Gouty; Febuxostat; Gout; Gout Suppressants; Humans; Male; Middle Aged; Primary Myelofibrosis; Uric Acid | 2018 |
Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
Topics: Adolescent; Adult; Allopurinol; Cohort Studies; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Time Factors; Transplant Recipients; Treatment Outcome; Uric Acid; Young Adult | 2019 |
Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Topics: Aged; Allopurinol; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Time Factors; Uric Acid | 2019 |
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Surveys; Prevalence; Probenecid; United States; Uric Acid; Uricosuric Agents; Young Adult | 2019 |
Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update.
Topics: Aged; Allopurinol; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Uric Acid; Xanthine Oxidase | 2019 |
The difficult relationship between uric acid and cardiovascular disease.
Topics: Aged; Allopurinol; Atrial Fibrillation; Cardiovascular Diseases; Febuxostat; Humans; Medicare; Risk Factors; United States; Uric Acid | 2019 |
Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Renal Insufficiency, Chronic; Republic of Korea; Treatment Outcome; Uric Acid | 2020 |
Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout.
Topics: Allopurinol; Computer Simulation; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Monitoring; Economics, Pharmaceutical; Febuxostat; Gout; Gout Suppressants; Humans; Insurance, Health, Reimbursement; Medication Adherence; Quality-Adjusted Life Years; Uric Acid; Xanthine Oxidase | 2019 |
Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study.
Topics: Adult; Aged; Biomarkers; Disease Progression; Febuxostat; Female; Humans; Hyperuricemia; Kaplan-Meier Estimate; Male; Middle Aged; Patient Outcome Assessment; Propensity Score; Public Health Surveillance; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2019 |
Cardiovascular disease and uric acid: is the not-so-innocent bystander becoming a true culprit and does the US black box warning for febuxostat indicate that not all uric acid lowering is beneficial?
Topics: Cardiovascular Diseases; Drug Labeling; Febuxostat; Humans; Thiazoles; Uric Acid | 2019 |
Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients.
Topics: Adult; Allografts; Allopurinol; Drug Substitution; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Kidney Transplantation; Male; Middle Aged; Transplant Recipients; Treatment Outcome; Uric Acid | 2019 |
Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
Topics: Adult; Allopurinol; Benzbromarone; Biomarkers; Cholesterol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Triglycerides; Uric Acid; Uricosuric Agents | 2019 |
Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits.
Topics: Aged; Alcohol Drinking; Allopurinol; Benzbromarone; Diet Therapy; Febuxostat; Female; Foot Joints; Fructose; Gout; Gout Suppressants; Humans; Male; Meat; Middle Aged; Prospective Studies; Purines; Shellfish; Tomography, X-Ray Computed; Uric Acid; Uricosuric Agents | 2020 |
Evaluation of Treatment Success Rate Among Antihyperuricemic Using Real-World Data.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2019 |
The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice.
Topics: Febuxostat; Female; Health Expenditures; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Prescription Drugs; Regression Analysis; Uric Acid | 2019 |
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Topics: Allopurinol; Benzbromarone; Disease Progression; Febuxostat; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Incidence; Male; Middle Aged; Recovery of Function; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid; Uricosuric Agents | 2019 |
Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Chemokine CCL2; Collagen; Diabetic Nephropathies; Febuxostat; Glucose Intolerance; Hyperglycemia; Hyperuricemia; Intercellular Adhesion Molecule-1; Interleukin-1beta; Interleukin-6; Kidney Glomerulus; Mice; Mice, Inbred C57BL; Mice, Obese; Oxidative Stress; Peptide Fragments; Uric Acid; Xanthine Oxidase | 2019 |
Role of allopurinol and febuxostat in the amelioration of dextran-induced colitis in rats.
Topics: Allopurinol; Animals; Anti-Inflammatory Agents; Colitis, Ulcerative; Colon; Dextran Sulfate; Drug Therapy, Combination; Febuxostat; Glutathione; Interleukin-1beta; Interleukin-6; Male; Malondialdehyde; Rats, Wistar; Sulfasalazine; Superoxide Dismutase; Uric Acid; Xanthine Oxidase | 2020 |
Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
Topics: Adult; Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome; Uric Acid | 2020 |
Burden and management of gout in a multi-ethnic Asian cohort.
Topics: Adult; Aged; Allopurinol; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Emergency Service, Hospital; Ethnicity; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Probenecid; Renal Insufficiency, Chronic; Severity of Illness Index; Singapore; Treatment Outcome; Uric Acid | 2020 |
Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models.
Topics: Animals; Benzbromarone; Disease Models, Animal; Febuxostat; HEK293 Cells; Humans; Hyperuricemia; Kidney; Male; Mice, Inbred ICR; Organic Anion Transporters; Organic Cation Transport Proteins; Uric Acid | 2019 |
Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Topics: Allopurinol; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Febuxostat; Hyperuricemia; Insulin Resistance; Lipid Peroxidation; Liver; Macrophage Activation; Mice, Inbred C57BL; Molecular Targeted Therapy; Uric Acid; Xanthine Oxidase | 2020 |
Efficacy and tolerability of febuxostat in gout patients on dialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Retrospective Studies; Treatment Outcome; Uric Acid | 2021 |
Bilateral Kienböck's disease concomitant with gouty arthritis.
Topics: Adult; Arthritis, Gouty; Diagnosis, Differential; Febuxostat; Gout Suppressants; Humans; Male; Osteonecrosis; Uric Acid; Wrist Joint | 2020 |
The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout.
Topics: Adult; Asian People; China; Cohort Studies; Double-Blind Method; Ethnicity; Febuxostat; Female; Gout; Humans; Hyperuricemia; Interleukin-17; Interleukin-6; Male; Middle Aged; Placebos; Random Allocation; Treatment Outcome; Tumor Necrosis Factor-alpha; Uric Acid | 2020 |
A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects.
Topics: Adult; Febuxostat; Female; Gout; Gout Suppressants; Healthy Volunteers; Humans; Kidney; Male; Renal Elimination; Uric Acid; Young Adult | 2020 |
Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Blood Pressure; Databases, Factual; Diastole; Disease Progression; Drug Prescriptions; Febuxostat; Female; Gout Suppressants; Heart Disease Risk Factors; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Hyperuricemia; Male; Middle Aged; Protective Factors; Retrospective Studies; Risk Assessment; Stroke Volume; Time Factors; Uric Acid; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Middle Aged; Retrospective Studies; Uric Acid | 2020 |
A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort
.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Uric Acid | 2020 |
[Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy].
Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Prevalence; Uric Acid | 2019 |
Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
Topics: Allopurinol; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospective Studies; Thailand; Thiazoles; Treatment Outcome; Uric Acid | 2021 |
Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Febuxostat; Female; Follow-Up Studies; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Taiwan; Uric Acid | 2020 |
Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Philippines; Treatment Outcome; Uric Acid | 2021 |
Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Retrospective Studies; Time Factors; Triglycerides; Uric Acid | 2020 |
Febuxostat mitigates concanavalin A-induced acute liver injury via modulation of MCP-1, IL-1β, TNF-α, neutrophil infiltration, and apoptosis in mice.
Topics: Animals; Apoptosis; Caspase 3; Chemokine CCL2; Concanavalin A; Febuxostat; Hepatitis; Interleukin-1beta; Liver; Male; Mice; Neutrophil Infiltration; Neutrophils; Peroxidase; Tumor Necrosis Factor-alpha; Uric Acid | 2020 |
Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design.
Topics: Allopurinol; Bayes Theorem; Clinical Trials, Phase III as Topic; Computer Simulation; Decision Theory; Drug Development; Economics, Pharmaceutical; Febuxostat; Gout; Humans; Hyperuricemia; Investments; Models, Biological; Models, Economic; Reimbursement Mechanisms; Research Design; Sample Size; Uncertainty; Uric Acid | 2021 |
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Topics: Allopurinol; Cardiovascular Diseases; Endothelial Cells; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2021 |
Xanthine oxidase inhibition attenuates doxorubicin-induced cardiotoxicity in mice.
Topics: Animals; Cardiotoxicity; Doxorubicin; Febuxostat; Mice; Uric Acid; Xanthine Oxidase | 2021 |
Urate Lowering With Combination Therapy in CKD: Reason for Optimism or Einstein's Definition of Insanity?
Topics: Albuminuria; Diabetes Mellitus, Type 2; Febuxostat; Humans; Naphthalenes; Propionates; Pyridines; Renal Insufficiency, Chronic; Uric Acid | 2021 |
Inosine induces acute hyperuricaemia in rhesus monkey (
Topics: Acute Disease; Allopurinol; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Febuxostat; Hyperuricemia; Imino Furanoses; Inosine; Macaca mulatta; Male; Pyrimidinones; Reproducibility of Results; Uric Acid | 2021 |
[Gout].
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Symptom Flare Up; Uric Acid | 2021 |
Drastic monosodium urate crystal dissolution with febuxostat and benzbromarone.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Solubility; Uric Acid | 2021 |
Ultrasound Evaluation of Three Outcome Domains in the Follow-up of Urate-Lowering Therapy in Gout: An Observational Study.
Topics: Adult; Arthritis; Bone Diseases; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Studies; Synovitis; Time Factors; Treatment Outcome; Ultrasonography; Uric Acid | 2021 |
Incorporating gout guideline advice into urate reports is associated with reduced hospital admissions: results of an observational study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Hospitals; Humans; Treatment Outcome; Uric Acid | 2022 |
Effects of Renal Function on Urinary Excretion and Serum Concentration of Uric Acid in Patients Treated with Febuxostat for Chronic Kidney Disease.
Topics: Febuxostat; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Retrospective Studies; Uric Acid | 2022 |
Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxid
Topics: Allopurinol; Carboxylic Acids; Drug Design; Enzyme Inhibitors; Febuxostat; Humans; Hydrogen Bonding; Models, Molecular; Pyrimidines; Structure-Activity Relationship; Uric Acid; Xanthine Oxidase | 2022 |
Colchicine use and the risk of CKD progression: a multicentre nested case-control study.
Topics: Case-Control Studies; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Treating gout - can hypouricemia produced by moderate doses of combined oral treatment give early treatment success? Preliminary observations.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Male; Treatment Outcome; Uric Acid | 2022 |
Tissue accumulation of neutrophil extracellular traps mediates muscle hyperalgesia in a mouse model.
Topics: Animals; Disease Models, Animal; DNA; Extracellular Traps; Febuxostat; Histones; Hyperalgesia; Mice; Muscles; Neutrophils; Uric Acid | 2022 |
Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria.
Topics: Adult; alpha-Galactosidase; Enzyme Replacement Therapy; Fabry Disease; Febuxostat; Glomerular Filtration Rate; Humans; Hyperuricemia; Proteinuria; Treatment Outcome; Uric Acid | 2022 |
Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
Topics: Aged; Allopurinol; Austria; Cardiovascular Diseases; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Hyperuricemia; Ischemic Stroke; Male; Retrospective Studies; Risk Factors; Uric Acid | 2022 |
POSSIBILITIES OF RENOPROTECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERURICEMIA.
Topics: Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Febuxostat Increases Ventricular Arrhythmogenesis Through Calcium Handling Dysregulation in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Topics: Allopurinol; Arrhythmias, Cardiac; Calcium; Extracellular Signal-Regulated MAP Kinases; Febuxostat; Humans; Induced Pluripotent Stem Cells; JNK Mitogen-Activated Protein Kinases; Myocytes, Cardiac; Uric Acid; Xanthine Oxidase | 2022 |
Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes.
Topics: Adipocytes; Allopurinol; Colchicine; Enzyme Inhibitors; Fatty Acids, Nonesterified; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Inflammation; Lipolysis; Prospective Studies; Uric Acid; Xanthine Oxidase | 2022 |
The safety and urate-lowering efficacy of febuxostat in patients undergoing peritoneal dialysis: a retrospective single-arm cohort study of 84 patients.
Topics: Cohort Studies; Disease Progression; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Peritoneal Dialysis; Retrospective Studies; Treatment Outcome; Uric Acid | 2022 |
Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2022 |
A modified xanthine oxidase cell model for screening of antihyperuricemic functional compounds.
Topics: Adenosine; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Hypoxanthines; Peptides; Uric Acid; Xanthine Oxidase | 2022 |
Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Insurance, Health; Japan; Risk Factors; Treatment Outcome; Uric Acid | 2023 |
A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout.
Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Uric Acid | 2023 |
Assessing tophaceous spinal gout treatment response using dual-energy CT as a point-of-care imaging modality: case report.
Topics: Aged; Febuxostat; Gout; Humans; Male; Point-of-Care Systems; Tomography, X-Ray Computed; Uric Acid | 2023 |
Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Febuxostat; Humans; Hyperuricemia; Indican; Prospective Studies; Uric Acid; Uricosuric Agents | 2022 |
Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway.
Topics: Animals; Diabetic Nephropathies; Endothelial Cells; Febuxostat; Humans; Male; Mice; Mice, Inbred C57BL; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; RNA, Messenger; Signal Transduction; Uric Acid; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xanthine Oxidase | 2023 |
Effects of Uric Acid-Lowering Therapy on the Kidney (HTR-2023-0096.R2).
Topics: Febuxostat; Humans; Hyperuricemia; Kidney; Uric Acid | 2023 |
Superiority of low-dose benzbromarone to low-dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2023 |
Towards the Development of Dual Hypouricemic and Anti-inflammatory Candidates: Design, Synthesis, Stability Studies and Biological Evaluation of Some Mutual Ester Prodrugs of Febuxostat-NSAIDs.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Esters; Febuxostat; Gout; Humans; Prodrugs; Uric Acid | 2023 |
Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Treatment Outcome; Uric Acid | 2023 |
Safety update: febuxostat and CVD.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2023 |
Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats.
Topics: Animals; Antioxidants; Atherosclerosis; Diet, High-Fat; Enzyme Inhibitors; Febuxostat; Lipids; Non-alcoholic Fatty Liver Disease; Rats; Rats, Inbred SHR; Uric Acid; Xanthine Oxidase | 2023 |
[Prevention of urolithiasis using febuxostat in patients with metabolic syndrome].
Topics: Febuxostat; Humans; Metabolic Syndrome; Uric Acid; Urinary Calculi; Urolithiasis | 2023 |
Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database.
Topics: Adult; Allopurinol; Colchicine; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Insurance Claim Review; Insurance, Health; Republic of Korea; Retrospective Studies; Uric Acid; Xanthine Oxidase; Young Adult | 2023 |